Immunoregulator

Details Immunoregulator Immunoregulator

2005-07-26

2005-07-26

Witz, Jean C. (Department: 1651)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C424S545000, C424S546000

Reexamination Certificate

active

06921751

ABSTRACT:
The invention relates to the field of immunology. Specifically, the invention relates to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides for an immunoregulator (IR), use of an IR in preparing a pharmaceutical composition for treating an immune-mediated disorder and a method for treating an immune-mediated disorder.

REFERENCES:
patent: 4977244 (1990-12-01), Muchmore et al.
patent: 5380668 (1995-01-01), Herron
patent: 5677275 (1997-10-01), Lunardi-Iskandar et al.
patent: 5851997 (1998-12-01), Harris
patent: 5854004 (1998-12-01), Czernilofsky et al.
patent: 5877148 (1999-03-01), Lunardi-Iskandar et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5968513 (1999-10-01), Gallo et al.
patent: 5997871 (1999-12-01), Gallo et al.
patent: 6319504 (2001-11-01), Gallo et al.
patent: 6361992 (2002-03-01), Szkudlinski et al.
patent: 6489296 (2002-12-01), Grinnell et al.
patent: 6583109 (2003-06-01), Gallo et al.
patent: 6596688 (2003-07-01), Gallo et al.
patent: 6620416 (2003-09-01), Gallo et al.
patent: 2002/0041871 (2002-04-01), Brudnak
patent: 2002/0064501 (2002-05-01), Khan et al.
patent: 2003/0049273 (2003-03-01), Gallo et al.
patent: 2003/0113733 (2003-06-01), Khan et al.
patent: 2003/0119720 (2003-06-01), Khan et al.
patent: 2003/0166556 (2003-09-01), Khan et al.
patent: 2003/0186244 (2003-10-01), Margus et al.
patent: 2003/0215434 (2003-11-01), Khan et al.
patent: 2003/0219425 (2003-11-01), Khan et al.
patent: 2003/0220257 (2003-11-01), Benner et al.
patent: 2003/0220258 (2003-11-01), Benner et al.
patent: 2003/0220259 (2003-11-01), Benner et al.
patent: 2003/0220260 (2003-11-01), Khan et al.
patent: 2003/0220261 (2003-11-01), Khan et al.
patent: 2003/0224995 (2003-12-01), Khan et al.
patent: 2004/0013661 (2004-01-01), Wensvoort et al.
patent: 3715662 (1987-11-01), None
patent: 19953339 (2001-05-01), None
patent: 1 138 692 (2001-10-01), None
patent: 1 300 418 (2003-04-01), None
patent: 2 706 772 (1994-12-01), None
patent: 96/04008 (1996-02-01), None
patent: 97/49373 (1997-12-01), None
patent: 97/49418 (1997-12-01), None
patent: 97/49432 (1997-12-01), None
patent: WO 97/49721 (1997-12-01), None
patent: WO 98/35691 (1998-08-01), None
patent: WO 99/59617 (1999-11-01), None
patent: WO 01/10907 (2001-02-01), None
patent: WO 01/10907 (2001-02-01), None
patent: WO 01/11048 (2001-02-01), None
patent: WO 01/11048 (2001-02-01), None
patent: WO 01/010907 (2001-02-01), None
patent: WO 01/72831 (2001-10-01), None
patent: WO 02/085117 (2002-10-01), None
patent: WO 03/029292 (2003-04-01), None
Christman et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy, Intens Care Med, 1998, pp. 1131-1138, vol. 24.
Jyonouchi et al., Proinflammatory and regulatory cytokine production accociated with innate and adaptive immune respones in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-179, vol. 120.
Kanungo et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, vol. 20.
Rohrig et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) onPlasmodium falciparumin vitro, Zentralblatt Bakt, 1999, pp. 89-99, vol. 289.
Tak et al., NF-kappaB: a key role in inflammatory diseases, J Clin Invest., 2001, pp. 7-11, vol. 107.
Tan et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, vol. 55.
Tovey et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-921, vol. 19.
Albini, A., et al., “Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin,” 17 Clinical & Experimental Metastasis 739 (1999).
Blackwell, Timothy, S., et al., “The Role of Nuclear Factor-kB in Cytokine Gene Regulation,” 17 Am. J. Respir. Cell Mol. Biol. 3-9 (1997).
Keller, S., et al., “Human Chorionic Gonadotropih (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells in Vitro,” 20(5-6) PLACENTA, p. A37 (Jul. 1999).
Khan, Nisar A., et al., “Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor,” 62(12) Human Immunology 1315-1323 (Dec. 2001).
Khan, Nisar A., et al., “Inhibition of Septic Shock in Mice by an Oligopeptide From the β-Chain of Human Chorionic Gonadotrophin Hormone,” 63(1) Human Immunology 1-7 (Jan. 2002).
Muchmore et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, Mar. 1997, pp. 881-886, vol. 118, No. 3.
Muchmore et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, Dec. 1984, pp. 1672-1685, vol. 160.
Patil, A., et al., “The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study,” 87 Acta Neurochir (WIEN) 76-78 (1987).
Slater, Lewis M., et al., “Decreased Mortality of Murine Graft-Versus-Host Disease by Human Chorionic gonadotropin,”23(1) Transplantations 103-104 (Jan. 1977).
Wulczyn, F. Gregory, et al., “The NF-kB/Rel and IkB gene families: mediators of immune response and inflammation,” 74(12) J. Mol. Med. 749-769 (1996).
Yamamoto, Y., et al., “Role of the NF-kB Pathway in the Pathogenesis of Human Disease States,” 1(3) Current Molecular Medicine 287-296 (Jul. 2001).
Connelly et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-3881, 166, The American Association of Immunologists, USA.
Friedlander, Tackling anthrax, Nature, Nov. 8, 2001, pp. 160-161, vol. 414.
Medzhitov, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, Nov. 2001, pp. 135-145, vol. 1.
PCT International Preliminary Examination Report, PCT/NI99/00313, dated Jul. 21, 2000, 6 pages.
PCT International Search Report, PCT/NL99/00313, dated Nov. 29, 1999, 3 pages.
Notification of Transmittal of the International Preliminary Examination Report.
International Search Report, publication date Jan. 13, 2000.
Lang et al., “Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin”,AIDS1997, vol. 11, No. 11, pp. 1333-1340.
Iskandar et al., “Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease”, Nature Medicine, Apr. 1998, vol. 4, No. 4, pp. 428-434.

Affiliated with

Also associated with

Rating

Immunoregulator does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoregulator, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoregulator will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3414939